This is a routine sell-to-cover transaction for tax withholding upon RSU vesting, not a discretionary insider sale. No bearish signal. Monitor for any subsequent open-market selling by insiders, which would be more informative. No trading action warranted.
ARTV drugs
ARTV drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 19 $8.55entry
- T+1 · 6mo ago −8.30%α −9.34% · $7.84
- T+5 · 6mo ago −10.76%α −13.06% · $7.63
- T+20 · 5mo ago +16.26%α +15.27% · $9.94
- T+60 · 3mo ago +32.16%α +25.87% · $11.30
Price Chart
How similar events traded
Executive Summary
Jennifer Bush, an officer and director of Artiva Biotherapeutics, filed a Form 144 to sell 9,000 shares of common stock as a sell-to-cover transaction for taxes owed on recently vested restricted stock units. At current market cap of ~$242M, this is a small, routine transaction with no material fundamental signal.
Key Facts
- Jennifer Bush (Officer/Director) filed Form 144 on 5/18/2026 proposing to sell 9,000 shares of Artiva Biotherapeutics (ARTV).
- The sale is explicitly a 'sell-to-cover transaction for taxes owed related to recent vesting of stock unit awards', not a discretionary open-market sale.
- Total estimated proceeds from the sale are immaterial relative to the company's ~$242M market cap.
- The shares were acquired via vesting of restricted stock units on 5/15/2026 as compensation for services.
Financial Impact
9,000 shares at ~$27/share implied by $242M market cap over ~9M shares outstanding is approximately $243K, a de minimis amount.
Risk Factors
- Lock-up or quiet-period implications not disclosed, general SEC Rule 144 requirements apply.
- If the company enters a material event window (earnings, data readout), this pre-scheduled tax sale could appear poorly timed, but the filing explicitly attributes it to tax obligations.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001621152-26-000003 |
| Document: 0001621152-26-000003-index.html | 0001621152-26-000003 |
| Document: 0001621152-26-000003.txt | 0001621152-26-000003 |
Track record
33 reports on ARTV
11 of 16 bullish or bearish reports moved the stock their way by T+20. Best: +66.32% at T+60 after the Jun 8, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 9, 20267d ago 8-K/A Bearish 7/10 Entry $4.06 Now $3.96 +2.46% settles Dec 9
- Nov 3, 202613d ago Insider Cluster Bearish 6/10 Entry $4.22 Now $3.96 +6.16% settles Dec 3
- Oct 27, 202620d ago 8-K Bearish 6/10 Entry $4.27 Now $3.96 +7.26% settles Nov 24
- Oct 6, 20265w ago 144 Neutral 3/10 Entry $7.00 to $4.21 Now $3.96 −43.43% ▼ −39.93% −38.69% vs SPY
- Sep 11, 20269w ago 8-K Neutral 3/10 Entry $10.14 to $6.77 Now $3.96 −60.95% ▼ −33.23% −35.50% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 4/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Neutral 3/10 Entry $10.42 to $6.80 Now $3.96 −62.00% ▼ −34.74% −37.12% vs SPY
- Sep 9, 20269w ago Insider Cluster Bearish 5/10 Entry $10.42 to $6.80 Now $3.96 +62.00% ▲ +34.74% +37.12% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers